niftify.in

niftify.in

Latest Wockhardt News

Stay Informed on Wockhardt Stock News: Access the latest Wockhardt stock news, industry updates, and quick information on Wockhardt stock buybacks,Wockhardt results, Wockhardt company analysis, Wockhardt live prices, Wockhardt dividends, Wockhardt bonus share, board meetings, lifetime highs, Wockhardt targets, lows, and growth stories with AI—all in one place.

The drug addresses a significant medical need, as existing treatments like Azithromycin face resistance issues or lack comprehensive coverage of respiratory pathogens
Business Line

Business Line

Wockhardt clinches BIRAC innovator award for novel antibiotic

The drug addresses a significant medical need, as existing treatments like Azithromycin face resistance issues or lack comprehensive coverage of respiratory pathogens

Mon, Sep 16, 2024

After ICICI and Wockhardt; M&M, Dr.Reddy's and Pidilite are the latest company names to be dragged in the Congress versus Sebi chief controversy. Here's a technical outlook on these stocks.
Business Standard

Business Standard

Congress vs Sebi chief Buch: Trading strategies in M&M, Pidilite, Wockhardt

After ICICI and Wockhardt; M&M, Dr.Reddy's and Pidilite are the latest company names to be dragged in the Congress versus Sebi chief controversy. Here's a technical outlook on these stocks.

Tue, Sep 10, 2024

Wockhardt has refuted allegations of conflict of interest and corruption made by the Congress party against SEBI chairperson Madhabi Puri Buch. The claims relate to rental payments by Carol Info Service, an affiliate of Wockhardt, which is involved in multiple cases with SEBI, including insider trading. Wockhardt termed the allegations as baseless and misleading.
The Economic Times

The Economic Times

Wockhardt says acted as per laws, denies Congress' charges over affiliate rental payments to Sebi chief

Wockhardt has refuted allegations of conflict of interest and corruption made by the Congress party against SEBI chairperson Madhabi Puri Buch. The claims relate to rental payments by Carol Info Service, an affiliate of Wockhardt, which is involved in multiple cases with SEBI, including insider trading. Wockhardt termed the allegations as baseless and misleading.

Sat, Sep 7, 2024

Drug firm Wockhardt has denied allegations regarding payment of rent by Carol Info Services and its connection with certain orders passed by SEBI in relation to the company.
"In this regard, we categorically deny these allegations and state that these allegations are completely baseless and misleading," Wockhardt said in a regulatory filing late Friday.
It said the company has acted and continues to act in compliance with all applicable laws.
On Friday, the Congress' media and publicity department head, Pawan Khera said that between 2018 and 2024, Madhabi Buch - as a whole-time member and later chairperson of Securities and Exchange Board of India (SEBI) - had been receiving rental income amounting to Rs 2.16 crore from Carol Info Services, a company affiliated to Wockhardt.
Mumbai-based Wockhardt was being investigated by SEBI for various cases, including that of insider trading during 2023, he said at a press conference at the AICC headquarters in Delhi.
Business Standard

Business Standard

Wockhardt denies Carol Info rent payment allegations, link with Sebi orders

Drug firm Wockhardt has denied allegations regarding payment of rent by Carol Info Services and its connection with certain orders passed by SEBI in relation to the company. "In this regard, we categorically deny these allegations and state that these allegations are completely baseless and misleading," Wockhardt said in a regulatory filing late Friday. It said the company has acted and continues to act in compliance with all applicable laws. On Friday, the Congress' media and publicity department head, Pawan Khera said that between 2018 and 2024, Madhabi Buch - as a whole-time member and later chairperson of Securities and Exchange Board of India (SEBI) - had been receiving rental income amounting to Rs 2.16 crore from Carol Info Services, a company affiliated to Wockhardt. Mumbai-based Wockhardt was being investigated by SEBI for various cases, including that of insider trading during 2023, he said at a press conference at the AICC headquarters in Delhi.

Sat, Sep 7, 2024

Wockhardt's statement comes after opposition Congress levelled fresh allegations of corruption and conflict of interest against the SEBI chairperson.
Mint

Mint

“Baseless, misleading”: Wockhardt refutes allegations of rent payment by Carol Info to SEBI chief Madhabi Buch

Wockhardt's statement comes after opposition Congress levelled fresh allegations of corruption and conflict of interest against the SEBI chairperson.

Sat, Sep 7, 2024

Congress leader Pawan Khera on Friday had accused Sebi chief Madhabi Puri Buch of conflict of interest with the pharma company.
The Economic Times

The Economic Times

Wockhardt denies allegations of rent payments connections to SEBI orders, claims them baseless

Congress leader Pawan Khera on Friday had accused Sebi chief Madhabi Puri Buch of conflict of interest with the pharma company.

Sat, Sep 7, 2024

Shares of Wockhardt Ltd ended at ₹1,034.60 on Friday (September 6), down by ₹54.45, or 5.00% on the BSE.
CNBC TV18

CNBC TV18

Wockhardt refutes allegations of rent payments linked to SEBI orders, labels claims baseless

Shares of Wockhardt Ltd ended at ₹1,034.60 on Friday (September 6), down by ₹54.45, or 5.00% on the BSE.

Sat, Sep 7, 2024

The Congress has accused Madhabi Puri Buch of receiving  ₹2.17 crore in rental income from a firm linked to Wockhardt, which was under investigation for insider trading. This is the latest in a series of allegations targeting the Sebi chair related to her past roles and investments.
Mint

Mint

Buch allegedly earned rent from Wockhardt firm while Sebi was probing the drugmaker

The Congress has accused Madhabi Puri Buch of receiving ₹2.17 crore in rental income from a firm linked to Wockhardt, which was under investigation for insider trading. This is the latest in a series of allegations targeting the Sebi chair related to her past roles and investments.

Fri, Sep 6, 2024

During a press conference today, Khera accused Buch of corruption and insider trading. He claimed that Buch and her husband own a property in Mumbai, which has been rented to Carol Info Services Ltd, a company affiliated with Wockhardt Ltd.
Mint

Mint

Wockhardt stock plunges 5% following Congress' allegations of corruption against SEBI chief Madhabi Buch

During a press conference today, Khera accused Buch of corruption and insider trading. He claimed that Buch and her husband own a property in Mumbai, which has been rented to Carol Info Services Ltd, a company affiliated with Wockhardt Ltd.

Fri, Sep 6, 2024

Income of Rs 2.16 cr from firm linked to Wockhardt, a company under investigation
Business Standard

Business Standard

Congress launches fresh attack on Sebi chief Buch over rental income

Income of Rs 2.16 cr from firm linked to Wockhardt, a company under investigation

Fri, Sep 6, 2024

This came after the Congress party accused Securities and Exchange Board of India (Sebi) chairperson Madhabi Puri Buch of a conflict of interest involving the pharmaceutical firm Wockhardt
Business Standard

Business Standard

Wockhardt falls 5% after Congress alleges Sebi head of conflict of interest

This came after the Congress party accused Securities and Exchange Board of India (Sebi) chairperson Madhabi Puri Buch of a conflict of interest involving the pharmaceutical firm Wockhardt

Fri, Sep 6, 2024

Wockhardt shares dropped 5% after Congress leader Pawan Khera accused SEBI chief Madhabi Puri Buch of corruption and insider trading. Khera alleged a conflict of interest due to Buch's property dealings with a Wockhardt subsidiary. Congress demands an independent inquiry to maintain trust in India's stock markets.
The Economic Times

The Economic Times

Wockhardt shares fall 5% as Congress accuses Sebi chief of conflict of interest, corruption

Wockhardt shares dropped 5% after Congress leader Pawan Khera accused SEBI chief Madhabi Puri Buch of corruption and insider trading. Khera alleged a conflict of interest due to Buch's property dealings with a Wockhardt subsidiary. Congress demands an independent inquiry to maintain trust in India's stock markets.

Fri, Sep 6, 2024

Congress has alleged that SEBI chief Buch received rent income from a firm linked to Wockhardt --a company that was being investigated by SEBI for various cases, including that of insider trading during 2023
Mint

Mint

Congress accuses SEBI chief Madhabi Buch of corruption: ‘Rent income from entity under probe for insider trading’

Congress has alleged that SEBI chief Buch received rent income from a firm linked to Wockhardt --a company that was being investigated by SEBI for various cases, including that of insider trading during 2023

Fri, Sep 6, 2024

This marked the first instance in US, where Zaynich had been used to combat a complex infection caused by extreme-drug-resistant pseudomonas
Business Line

Business Line

Wockhardt stock soars over 19% after its investigational antibiotic Zaynich successfully treats cancer patient in US

This marked the first instance in US, where Zaynich had been used to combat a complex infection caused by extreme-drug-resistant pseudomonas

Mon, Jul 1, 2024

Global launch in FY26 after multinational clinical trial ends
Business Standard

Business Standard

Mumbai-based Wockhardt to launch its novel antibiotic Zaynich by FY25-end

Global launch in FY26 after multinational clinical trial ends

Fri, Jun 28, 2024

With strong financial backing and successful research, Wockhardt is poised for the launch of Zaynich, an antibiotic targeting high resistance levels globally. The company's strategic pricing and partnership approaches enhance its market penetration, setting the stage for a significant impact on the pharmaceutical industry.
The Economic Times

The Economic Times

Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26

With strong financial backing and successful research, Wockhardt is poised for the launch of Zaynich, an antibiotic targeting high resistance levels globally. The company's strategic pricing and partnership approaches enhance its market penetration, setting the stage for a significant impact on the pharmaceutical industry.

Fri, Jun 28, 2024